KASTELEIN JOHANNES JACOB PIETER (Chief Scientific Officer) sold 59.1% of their position (100K shares) of NEWAMSTERDAM PHARMA CO N.V. on the open market
Open‑market sale worth $2.47M — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 8/25/2025ACC: 0000950170-25-111241
DirectorOfficer· Chief Scientific Officer
Since Mar 2026
-100K
Net shares
Net seller
$2.47M
Total sold
3
Open market trades
0B · 3S
3
Total transactions
100K disposed
Non-Derivative Transactions3
Ordinary Shares
Indirect
Shares
−50K
Price / share
$24.29
Trade value
$1.21M
% of position
29.5%
8/21/2025
169.30K→119.30K
Ordinary Shares
Indirect
Shares
−42.34K
Price / share
$25.08
Trade value
$1.06M
% of position
35.5%
8/22/2025
119.30K→76.96K
Ordinary Shares
Indirect
Shares
−7.66K
Price / share
$25.49
Trade value
$195.20K
% of position
10.0%
8/22/2025
76.96K→69.30K
Total
Net shares
−100K
Net value
-$2.47M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Indirect | 8/21/2025 | S · Sale | −50K | $24.29 | $1.21M | 29.5% | 169.30K | 119.30K |
| Ordinary Shares Indirect | 8/22/2025 | S · Sale | −42.34K | $25.08 | $1.06M | 35.5% | 119.30K | 76.96K |
| Ordinary Shares Indirect | 8/22/2025 | S · Sale | −7.66K | $25.49 | $195.20K | 10.0% | 76.96K | 69.30K |
| Total | −100K | -$2.47M | ||||||
Derivative Transactions0
No derivative transactions reported